160 related articles for article (PubMed ID: 2895504)
21. 5-HT receptor regulation of neurotransmitter release.
Fink KB; Göthert M
Pharmacol Rev; 2007 Dec; 59(4):360-417. PubMed ID: 18160701
[TBL] [Abstract][Full Text] [Related]
22. [Dopamine and the central nervous system].
Bruno A; Cumer Bruno S
Riv Neurobiol; 1965; 11(4):813-49. PubMed ID: 5329676
[No Abstract] [Full Text] [Related]
23. Neurochemical and neuropharmacological indications for the involvement of GABA and glycine receptors in neuropsychiatric disorders.
Lloyd KG; DeMontis G; Broekkamp CL; Thuret F; Worms P
Adv Biochem Psychopharmacol; 1983; 37():137-48. PubMed ID: 6138947
[TBL] [Abstract][Full Text] [Related]
24. GABA(B) receptors and synaptic modulation.
Kornau HC
Cell Tissue Res; 2006 Nov; 326(2):517-33. PubMed ID: 16932937
[TBL] [Abstract][Full Text] [Related]
25. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
26. [Chemical neurotransmission in the central nervous system].
Ahtee L
Duodecim; 1969; 85(14):872-82. PubMed ID: 4312228
[No Abstract] [Full Text] [Related]
27. [Biochemistry of neuronal transmission. Pharmacology of parkinsonism].
Lombardo L
Gac Med Mex; 1981 Dec; 117(12):476-8. PubMed ID: 6123462
[No Abstract] [Full Text] [Related]
28. [Biochemical aspects of schizophrenia].
Sano A; Kakimoto Y
Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1380-7. PubMed ID: 1972588
[No Abstract] [Full Text] [Related]
29. [Cerebral amines].
Nihon Rinsho; 1976 Sep; 34(9):2746-62. PubMed ID: 11360
[No Abstract] [Full Text] [Related]
30. Developments in the pharmacology and therapeutics of parkinsonism.
Calne DB
Ann Neurol; 1977 Feb; 1(2):111-9. PubMed ID: 18978
[No Abstract] [Full Text] [Related]
31. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
Quinones MP; Kaddurah-Daouk R
Neurobiol Dis; 2009 Aug; 35(2):165-76. PubMed ID: 19303440
[TBL] [Abstract][Full Text] [Related]
32. The biochemistry of mental illness.
Smith BH; Rosich-Pla A
Psychosomatics; 1979 Apr; 20(4):278-9, 282-3. PubMed ID: 35811
[No Abstract] [Full Text] [Related]
33. Integrating the neurobiology of schizophrenia. Preface.
Abi-Dargham A; Guillin O
Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
[No Abstract] [Full Text] [Related]
34. Glutamatergic hypothesis of schizophrenia: involvement of Na+/K+-dependent glutamate transport.
Nanitsos EK; Nguyen KT; St'astný F; Balcar VJ
J Biomed Sci; 2005 Dec; 12(6):975-84. PubMed ID: 16228297
[TBL] [Abstract][Full Text] [Related]
35. Dopaminergic regulation of cholinergic neurons in the striatum: relation to Parkinsonism.
Bartholini G; Lloyd KG; Stadler H
Adv Neurol; 1974; 5():11-4. PubMed ID: 4440567
[No Abstract] [Full Text] [Related]
36. The structure and mechanism of neurotransmitter receptors. Implications for the structure and function of the central nervous system.
Strange PG
Biochem J; 1988 Jan; 249(2):309-18. PubMed ID: 2893605
[No Abstract] [Full Text] [Related]
37. [Neurotransmitters and neuropeptides in schizophrenia].
Toru M; Ichikawa H
Tanpakushitsu Kakusan Koso; 1984 Dec; 29(14):1838-54. PubMed ID: 6085408
[No Abstract] [Full Text] [Related]
38. [Biological psychiatry (neuropsychiatry)--status and perspectives for for the 1990s].
Rosenberg R
Nord Med; 1993; 108(5):139-44. PubMed ID: 8098866
[TBL] [Abstract][Full Text] [Related]
39. Substantial changes in central nervous system neurotransmitters and neuromodulators accompany phase change in the locust.
Rogers SM; Matheson T; Sasaki K; Kendrick K; Simpson SJ; Burrows M
J Exp Biol; 2004 Sep; 207(Pt 20):3603-17. PubMed ID: 15339956
[TBL] [Abstract][Full Text] [Related]
40. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
Zhu BT
Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
